Big firms afraid to criticize Medco deal: senator

	Tweet

Major firms which oppose a proposed deal to merge Medco Health Solutions Inc and Express Scripts Inc feared retaliation and declined to publicly discuss the deal, said Senator Herb Kohl, head of the Senate Judiciary Committee’s antitrust panel.

Senator Richard Blumenthal also took aim at the estimated $26 billion deal, saying it was “problematic” and asking the companies if they would be willing to accept major divestments to win approval for the deal.

The proposed transaction, which was announced in July, would combine two of the three U.S. pharmacy benefit managers (PBMs) that are large enough to manage prescription drug benefits for nationwide companies.

Kohl said that, post-merger, Express Scripts and Medco would have 60 percent of the U.S. mail order prescription drug business and 50 percent of the specialty drug market.

“It is notable that no large employer who privately expressed concerns to us wished to testify at today’s hearing, often telling our staff that they feared retaliation from the large PBMs with whom they must do business,” Kohl said.

The chief executives of the two companies, for their part, argued that they were working to push prescription drug prices down while protecting customers by guarding against negative drug interactions.

“We are going to lower prescription drug costs that are far too high,” Express Scripts CEO George Paz said in testimony prepared for the Senate Judiciary Committee’s antitrust panel.

Medco CEO David Snow agreed, saying, “We drive drug costs down for our clients and patients in service to our more than 65 million members across America.”

But Blumenthal also questioned whether the deal could get approved by the Federal Trade Commission, saying the companies would be by far the largest PBM if the merger goes through.

“Under the law, it is problematic,” he said. “I’m interested in knowing what you will do to make this merger more acceptable.”

WHO’S KILLING COMMUNITY PHARMACIES?

Senators Al Franken and Amy Klobuchar, both of Minnesota, asked about the PBMs’ relationship with community pharmacies.

Community pharmacies, under huge pressure from big box stores which offer low prices, have complained that they compete against the PBMs. However, the community drugstores also service PBM customers at rates set by the PBMs.

“PBMs directly set the reimbursement rates for community pharmacies and for us, it’s take it or leave it,” said Susan Sutter, who owns three Wisconsin pharmacies.

The FTC is assessing the merger to make sure it complies with antitrust law. A group of about two dozen state attorneys general are also looking at it, and could conceivably challenge the deal on their own.

An antitrust subcommittee at the House of Representatives has also held hearings to discuss the deal, although lawmakers have no formal power to stop any transaction.

###

By Diane Bartz

WASHINGTON

RELATED STORIES:
Lesbian, Gay, Bisexual, and Transgender Health: A Neglected Issue   Cost of Obesity   Japan cellphone firms find no DNA damage from waves   Flu vaccines for nursing home workers effective in reducing outbreaks: study   Anti-poverty campaign leaving women behind   Expert Available to Discuss Status of Tuberculosis in America   Influenza monitoring by the US military   Smoking could kill 1 billion this century   FDA seizes potentially deadly hospital beds   N.C. Tobacco Prevention Programs Are Saving Lives and Money   Clinton hails China’s AIDS progress, offers help   Tough seat belt laws can lower crash deaths - group

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]